Skip to main content

Table 1 Reagents and results in immunohistochemistry.

From: Urinary bladder carcinoma with triplicate differentiations into giant cell sarcomatoid carcinoma, squamous cell carcinoma, and papillary urothelial transitional cell carcinoma: a case report

Antigens Antibodies (clone) Sources Giant cell sarcomatoid SCC TCC
Pancytokeratin AE1/3 Dako Corp. Glostrup, Denmark ++ +++ +++
Pancytokeratin CAM5.2 Becton Dickinson Co. CA, USA ++ +++ +++
HMWCK 34βE12 Dako + + ++
CK5/6 D5/16 Dako + ++ ++
CK7 N1626 Dako + + ++
CK8 35βH11 Dako + ++ ++
CK14 LL002 Novocastra, Newcastle upon type, UK + + ++
CK 18 DC10 Dako ++ +++ +++
CK 19 RCK 108 Progen, Heidelberg, Germany - + +
CK20 K20.8 Dako - - ++
EMA E29 Dako + + ++
Chromogranin DAK-A3 Dako - - -
Synaptophysin Polyconal Dako - - -
CD56 MOC-1 Dako - - -
CD68 KP-1 Dako - - -
Melanosome HMB45 Dako - - -
Vimentin Vim 3B4 Dako +++ - -
Desmin D33 Dako - - -
S100 protein polyclonal Dako - - -
ASMA 1A4 Dako - - -
Myoglobin polyclonal Dako - - -
CD34 NU-4A1 Nichirei, Tokyo, Japn - - -
p53 protein DO-7 Dako ++ ++ +
Ki-67 MIB-I Dako 72% 67% 32%
  1. SCC, squamous cell carcinoma; TCC, transitional cell carcinoma area; +++, 67-100% positive; ++, 33-66%; +, 1-33% positive; -, negative; HMWCK, high molecular weight cytokerain; CK, cytokeratin; EMA, epithelial membrane antigen; ASMA, α-smooth muscle antigen.